KERYX BIOPHARMACEUTICALS INC FILES (8-K) Disclosing Change in Directors or Principal Officers, Financial Statements and Exhibits

Edgar Glimpses |

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

           Appointment of Certain Officers; Compensatory Arrangements of Certain

(b) On , John P. Butler notified Keryx Biopharmaceuticals, Inc. (the "Company") that he was resigning from the Company's Board of Directors (the "Board") effective as of . Mr. Butler did not communicate to the Company any disagreements regarding the Company's operations, policies or practices in connection with his resignation, nor is the Company aware of any such disagreements.

(d) On , pursuant to Section 3.05 of the Company's Amended and Restated Bylaws, the Board appointed Mark J. Enyedy as an independent director of the Board, effective as of , to fill the vacancy created by Mr. Butler's resignation. Mr. Enyedy is to serve as a director until his term expires at the 2018 annual meeting of stockholders. Mr. Enyedy was appointed to the Nominating & Corporate Governance Committee of the Board.

Mr. Enyedy, age 53, has over 20 years of experience in the life sciences industry. He is currently the President and Chief Executive Officer of ImmunoGen, Inc., a publicly traded biopharmaceutical company, a position he has held since . Prior to joining ImmunoGen, Mr. Enyedy served in various executive capacities at Shire plc, a pharmaceutical company, from 2013 to , including as Executive Vice President and Head of Corporate Development from 2014 to , where he led Shire's strategy, M&A, and corporate planning functions and provided commercial oversight of Shire's pre-Phase 3 portfolio. Prior to joining Shire he served as Chief Executive Officer and a director of Proteostasis Therapeutics, Inc., a biopharmaceutical company, from 2011 to 2013. Prior to joining Proteostasis he served for 15 years at Genzyme Corporation, a biopharmaceutical company, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Mr. Enyedy holds a JD from Harvard Law School and practiced law prior to joining Genzyme. Mr. Enyedy is also a director of Fate Therapeutics, Inc., a publicly traded biopharmaceutical company.

Mr. Enyedy was appointed to the Board pursuant to the right of the Company's largest stockholder, The Baupost Group, L.L.C., to designate a member of the Board. There are no arrangements or understandings between Mr. Enyedy and any other person pursuant to which he was elected as a director, nor are there any transactions between Mr. Enyedy and the Company that would be reportable under Item 404(a) of Regulation S-K. Mr. Enyedy will receive customary compensation in accordance with the Company's director compensation policy.

In addition, in connection with Mr. Butler's resignation, the Board appointed Michael Rogers, a current member of the Board, to serve as the Chairman of the Board, effective as of .

Keryx announced Mr. Butler's resignation, the appointment of Mr. Enyedy to the Board and the appointment of Mr. Rogers as Chairman of the Board via press release on . A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 5.02.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed herewith:

99.1      Press release issued by Keryx Biopharmaceuticals, Inc., dated


DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.